<DOC>
	<DOCNO>NCT02836457</DOCNO>
	<brief_summary>The primary objective study estimate real-world safety profile Eliquis Japanese Venous Thromboembolism patient estimate risk factor likely affect incidence bleeding . Lastly , secondary objective study estimate real-world effectiveness profile Eliquis Japanese Venous Thromboembolism patient .</brief_summary>
	<brief_title>ELIQUIS ( APIXABAN ) Regulatory Post-Marketing Surveillance In Clinical Practice Venous Thromboembolism ( VTE ) Treatment Prevention Of Recurrent VTE</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Patients initiate Eliquis treatment VTE prevention recurrent VTE first time Prior treatment Eliquis nonvalvular atrial fibrillation VTE Patients initiate Eliquis treatment atrial fibrillation Offlabel use Eliquis Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>